

# Novel Enantioselective Synthesis of Penaresidin A and *Allo*-penaresidin A via the Construction of a Highly Functionalized Azetidine

Ding-Guo Liu and Guo-Qiang Lin\*

Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences,  
354 Fenglin Lu, Shanghai, 200032, China


Received 22 September 1998; revised 28 October 1998; accepted 30 October 1998

**Abstract** : A new and highly enantioselective synthesis of penaresidin A has been achieved via the construction of a highly functionalized azetidine with the requisite stereogenic centers, which can also be regarded as an advanced intermediate for the synthesis of penaresidin B and penazetidine A.

© 1998 Elsevier Science Ltd. All rights reserved.


**Keywords** : Alkaloids; Azetidine; Cyclization; Wittig reactions; Reduction

In 1991, penaresidin A (**1**) and B (**2**), the first two sphingosine-derived alkaloids possessing an azetidine ring, were isolated from the Okinawan marine sponge *Penares* sp.[1]. Tested as an inseparable mixture, these two compounds exhibit potent actomyosin ATPase-activating activity. After structural characterization through spectroscopic methods [1,2] supplemented by synthetic studies [3,4], the absolute configurations of five stereogenic centers in **1a** were established to be *2S,3R,4S,15S* and *16S*. In 1994, from the Indo-Pacific marine sponge *Penares*



Scheme 1

*sollasi*, Crews *et al* [5] isolated a structurally related alkaloid, penazetidine A (**3**), which possesses potent protein kinase C inhibitory activity. Additionally, the structure of the substituted azetidine in **3** was confirmed to be the same as that in penaresidins by synthesis [6] in 1996. During our enantioselective synthetic studies of penaresidins, two groups [4,7] have reported their strategies to penaresidin A from the same material of Garner aldehyde since 1995. In addition, there were also two reports [4b,8] about the synthesis of penaresidin B. In early this year, we reported the synthesis [9] of two penaresidin A analogues from divinylcarbinol (**5**). However, we had to change our strategy due to some unconquerable difficulty [10] in the cyclization to form an azetidine moiety with the desired stereogenic centers. In this paper, we wish to communicate our new strategy for the total synthesis of penaresidin A (**1a**) and its stereoisomer **1b** from the same material **5** based on the construction of a highly functionalized azetidine **4** with the requisite stereogenic centers.




**Scheme 2**

Reagents and Conditions: a) TBHP, D-(-)-DIPT, Ti(*O-iso-Pr*)<sub>4</sub>, 4Å MS, CH<sub>2</sub>Cl<sub>2</sub>, -20°C, 10 days, 65%; b) 0.5 N NaOH, -10°C, 89%; c) NaH, BnBr, Bu<sub>4</sub>NI, THF, 87%; d) i) DHQ-PYR, K<sub>2</sub>[OsO<sub>2</sub>(OH)<sub>4</sub>], K<sub>2</sub>CO<sub>3</sub>, K<sub>3</sub>[Fe(CN)<sub>6</sub>], *t*-BuOH/H<sub>2</sub>O(1:1) ii) 2,2-dimethoxypropane, PTS, CH<sub>2</sub>Cl<sub>2</sub>, 73% (2 steps); e) NaN<sub>3</sub>, NH<sub>4</sub>Cl, CH<sub>3</sub>OCH<sub>2</sub>CH<sub>2</sub>OH/H<sub>2</sub>O (8:1), reflux, 87%; f) i) LiAlH<sub>4</sub>, THF; ii) TsCl, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 92% (2 steps); g) 2N HCl/CH<sub>3</sub>OH(1:1), 40°C, 95%; h) TBSCl, DMAP, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 100%; i) PPh<sub>3</sub>, DEAD, CH<sub>2</sub>Cl<sub>2</sub>, 60%; j) *n*-Bu<sub>4</sub>NF, THF, 100%; k) (COCl)<sub>2</sub>, DMSO, -78°C, then NEt<sub>3</sub>, 95%.

As shown in Scheme 2, compound **6** was readily prepared from **5** in two steps as described in ref [11] and the resulting hydroxyl group was protected as benzyl ether to furnish **7**. Sharpless asymmetric dihydroxylation [12] of **7** with DHQ-PYR as ligand was followed by isopropylidenation of the resultant diol to yield **8** with high stereoselectivity (d.e, 11:1). Regioselective cleavage [13] of the epoxide **8** afforded **9** in 87% yield, whose hydroxyl group was benzylated to give **10**. The next conversion of **10** to **12** was accomplished by the efficient three step sequence. Reduction of **10** with LiAlH<sub>4</sub> and subsequent tosylation of the resulting amino group followed by ring cleavage of the acetonide with 2N HCl in CH<sub>3</sub>OH (1:1) at 40°C

afforded **12** in 87% overall yield. Attempt to regioselectively protect the primary hydroxyl group in **12** with TBSCl and imidazole in DMF at 0°C resulted in modest conversion of the material. Finally, compound **12** was converted quantitatively to **13** while treated with TBSCl and NEt<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> at room temperature in the presence of a catalytic amount of DMAP [14]. The next crucial cyclization of **13** was carried out smoothly under Mitsunobu [15] conditions to furnish **14** in 60% yield. Finally, deprotection of the TBS group was accomplished effectively by reaction of **14** with *n*-Bu<sub>4</sub>NF in THF. To this stage, we completed the construction of a highly functionalized azetidine **4** [16], which can be regarded as a key intermediate for penaresidins and penazetidine A. In our attempt to complete the synthesis of penaresidin A, it was necessary to obtain an aldehyde **15**, which was accessible by Swern oxidation of alcohol **4**. The crude **15** was directly used without further purification in the next step.



**Scheme 3**

Reagents and Conditions: l) HBr, benzene, reflux, 80%; m) (COCl)<sub>2</sub>, DMSO, CH<sub>2</sub>Cl<sub>2</sub>, -78°C, then NEt<sub>3</sub>; n) Z-(*S,S*)-crotylboronate, 4Å MS, toluene, -78°C, 88% (2 steps); o) Ac<sub>2</sub>O, pyridine, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 96%; p) PPh<sub>3</sub>, 130°C, 95%; q) NaDMSO, THF, -10°C, then -78°C, **15**, 60%; r) NH<sub>2</sub>OH, EtOAc, DMF, 90-100°C, 92%; s) LiAlH<sub>4</sub>, Et<sub>2</sub>O, 85%; t) 10% Pd/C, H<sub>2</sub>, 95% EtOH, 79%; u) Na, naphthalene, DME, -60°C; v) Ac<sub>2</sub>O, pyridine, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 86% (2 steps); w) Z-(*R,R*)-crotylboronate, 4Å MS, toluene, -78°C, 86% (2 steps).

The synthesis of penaresidin A and that of *allo*-penaresidin A are summarized in Scheme 3. Compounds **18a** and **18b** were prepared according to the known protocol [7] from 1,10-decanediol. The bromo alcohol **18a** was protected as *O*-acetyl derivative and then converted to Wittig salt **20a**. With the two requisite fragments in hand, the Wittig coupling reaction was explored at -78°C and then warmed to room temperature with NaHMDS as the base. However,

the yield was rather poor (20%). When NaHMDS was replaced by NaDMSO, fortunately, the yield was improved to give a mixture of *Z* and *E* -**21a** in 60% yield. Treatment of **21a** with catalytic hydrogenation on 10% Pd/C failed to afford the desired product because of the high tendency to hydrogenolysis of the vinyl azetidine. Diimide reduction [17] of the double bonds led to produce **22a** and partial deacylation product **23a**. Conversion of **22a** to **23a** was smoothly completed by reduction with LiAlH<sub>4</sub>. Finally, removal of the both benzyl and Ts groups of **22a** completed the synthesis of penaresidin A (**1a**), which was converted to the known tetraacetate **25a** [ $\alpha$ ]<sub>D</sub> = + 34.6° (c 0.68, CHCl<sub>3</sub>) (lit.[4] : [ $\alpha$ ]<sub>D</sub> = + 38° (c 0.378, CHCl<sub>3</sub>)). For the synthesis of (15*R*,16*R*)-*allo*-penaresidin A, the intermediate **18b** was subjected to the same procedure as mentioned before, and the product **1b** was acetylated to afford the tetraacetyl derivative **25b** [ $\alpha$ ]<sub>D</sub> = + 42.6° (c 1.30, CHCl<sub>3</sub>) (lit.[4] : [ $\alpha$ ]<sub>D</sub> = + 42° (c 0.41, CHCl<sub>3</sub>)). Their physical data were completely identical with the reported values in all respects.

In summary, our process starting from divinylcarbinol provides a new synthetic strategy and represents a short and general approach to penaresidins and penazetidine A.

**Acknowledgment:** We are grateful to the National Natural Science Foundation of China (No.297912005) and the Chinese Academy of Sciences (KY952-S1-501) for the financial support.

#### References and Notes

- [1] Kobayashi, J.; Cheng, J.-F.; Ishibashi, M.; Wälcchli, M. R.; Yamamura, S.; Ohizumi, Y. *J. Chem. Soc., Perkin Trans. I*, **1991**, 1135-1137.
  - [2] Kobayashi, J.; Tsuda, M.; Cheng, J.-F.; Ishibashi, M.; Takikawa, H.; Mori, K. *Tetrahedron Lett.*, **1996**, 37, 6775-6776.
  - [3] Hiraki, T.; Yamaguchi, Y.; Kamikawa, T. *Tetrahedron Lett.*, **1995**, 36, 4841-4844.
  - [4] (a) Takikawa, H.; Maeda, T.; Mori, K. *Tetrahedron Lett.*, **1995**, 36, 7689-7692.  
(b) Takikawa, H.; Maeda, T.; Seki, M.; Koshino, H.; Mori, K. *J. Chem. Soc., Perkin Trans. I*, **1997**, 97-111.
  - [5] Alvi, K. A.; Jaspars, M.; Crews, P. *Bioorg. Biomed. Chem. Lett.*, **1994**, 4, 2447-2450.
  - [6] Yajima, A.; Takikawa, H.; Mori, K. *Liebigs Ann.*, **1996**, 1083-1089.
  - [7] Knapp, S.; Dong, Y.-H. *Tetrahedron Lett.*, **1997**, 38, 3813-3816.
  - [8] Yoda, H.; Oguchi, T.; Takabe, K. *Tetrahedron Lett.*, **1997**, 38, 3283-3284.
  - [9] Lin, G. Q.; Liu, D. G. *Heterocycles*, **1998**, 47, 337-348.
  - [10] Compound **26** was converted to **27** in two steps, and the diastereoselectivity in the reduction was 9:1. However, when compound **27** was subjected to the following two procedures, no desired product of cyclization was afforded: 1) PPh<sub>3</sub>, DEAD, THF; 2) i. MsCl, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; ii. NaH, DMF.
- 
- [11] Jäger, V.; Schröter, D.; Koppenhoefer, B. *Tetrahedron*, **1991**, 47, 2195-2210.
  - [12] Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. *Chem. Rev.*, **1994**, 94, 2483-2547.
  - [13] Behrens, C. H.; Sharpless, K. B. *J. Org. Chem.*, **1985**, 50, 5696-5704.
  - [14] Chaudhary, S. K.; Hernandez, O. *Tetrahedron Lett.*, **1979**, 20, 99-102.
  - [15] Henry, J. R.; Marcin, L. R.; McIntosh, M. C.; Scola, P. M.; Harris, G. D., Jr.; Weinreb, S. M.; *Tetrahedron Lett.*, **1989**, 30, 5709-5703.
  - [16] Properties of compound **4**: [ $\alpha$ ]<sub>D</sub> = + 47.1° (c 1.16, CHCl<sub>3</sub>); IR (film): 3524, 2927, 2868, 1599, 1497, 1455, 1335, 1207, 1154, 1093, 1043, 914, 815, 738, 699, 680 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$  ppm: 2.35 (3H, s, Ar-CH<sub>3</sub>), 2.92 (1H, b, OH), 3.46 (1H, dd, *J* = 3.1, 10.6 Hz, 1-H), 3.58 (1H, dd, *J* = 4.8, 10.6 Hz, 1-H'), 3.91-4.11 (2H, m, 5-H), 4.30-4.43 (5H, m), 4.45, 4.50 (2H, AB, *J*<sub>AB</sub> = 12.0 Hz, Bn-H), 7.10-7.40 (12H, m, Ar-H), 7.71 (2H, d, *J* = 8.3 Hz, Ar-H); MS (*m/z*, %): 468 (*M*<sup>+</sup>+1, 1.47), 312 (5.86), 181 (6.73), 92 (10.00), 91 (100), 65 (13.01). (Found: C, 66.71; H, 5.92; N, 2.71. C<sub>26</sub>H<sub>29</sub>NO<sub>3</sub>S; requires: C, 66.79; H, 6.25; N, 3.00%).
  - [17] Wade, P. A.; Amin, N. V. *Synth. Commun.*, **1982**, 12, 287-291.